Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016

Kisile Mikuo Olive; Kabongo Mpolesha Jean Marie; Claudia Manini

doi:doi:10.11648/j.iji.20210902.12

| Peer-Reviewed

Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016

Kisile Mikuo Olive, Kabongo Mpolesha Jean Marie, Claudia Manini

Published in International Journal of Immunology (Volume 9, Issue 2)

Received: 10 March 2021 Accepted: 29 April 2021 Published: 14 May 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The goal is to determine immunohistochemical histopathological profile and biomolecular level of Central nerve Tumors in Kinshasa, DRC. According to the classification of the World Health Organization (WHO) 2016. Our study is described on a series of cases that were studied using standard histopathological techniques, before undergoing specific immunohistochemical techniques for the detection of anti-IDH1antibodies in gliomas and biomolecular ones in the search for 1p19q deletion. Central nerve tumors account for 0.18% of all conditions, over a period of time. Meningothelial-type meningioma was the most common (60.9%). The most affected age group is over 50. The distribution of tumors by sex shows a predominance of woman (67.1%). The gliomas had constituted 29.6% of all nerve tumors recorded over the period considered and whose predominance was constituted by oligoastrocytomas with 42.1%. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II oligoastrocytoma with 6.6%. Our study showed that central nerve tumors account for 0.18 of all conditions, gliomas are made up of 29.6% of all nerve tumors listed with a predominance of oligoastrocytomas. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II.

Published in	International Journal of Immunology (Volume 9, Issue 2)
DOI	10.11648/j.iji.20210902.12
Page(s)	29-36
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Tumors, Glioma, Histopathologic, Immunohistochemestry, Biomolecular, Classification WHO 2016

References

[1]	DN LOUIS, WIESTLER OD, and CAVENEE WK. WHO classification of tumors of the central nervous system. Revised 4^th edition, Lyon: International Agency for Research on Cancer (IARC) 2016.
[2]	WELLER M, STUPP R, HEGI ME and coll. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012; Suppl. 4: iv100-108.
[3]	VAN DEN BENT MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010 Sept; 1205: 297-304.
[4]	BRAT DJ, VERHAAK RG, ALDAPE KD and coll. Cancer Genome Atlas Research Network, Comprehensive, Integrative Genomic Analysis of diffuse Lower-Grade Gliomas. N Engl J Med. Jun 25; 372 (26): 2481-2498.
[5]	SUZUKI H, AOKI K, SATO Y and coll. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015 May; 47(5): 458-468,
[6]	WIESTLER B, CAPPER D, SILL M and coll. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathology 2014 Oct; 128 (4): 561-571.
[7]	http://globcan.iarc.fr/Lyon,10.1186/2042-6410-3-3
[8]	KEITA AD, KANE M, GUINTO CO and coll. Contribution of tomodensitometry in the management of brain tumorat the G point HOSPITAL in Mali. Médical Mali 2007; 22 (2): 14-18.
[9]	BELOT A, VELTEN M, GROSCLAUDE P et al. National estimate of cancer in incidence and mortality in France between 1980 and 2005. Saint-Maurice (Fra):French institute for public Health Surveillance, décember 2008, p132.
[10]	BELOT A and coll. Cancer incidence and mortality in France over the period: 1980-2005. Epidemiology and Public Health Review, 2008, 56:159-175.
[11]	FOUATIH Z and coll. The cancer registry of Oran. Ten years of registration: 1996-2005. Oran, University of Oran, Faculty of Medecine, 2008.
[12]	Rabat Cancer Registry. Incidence of cancer in Rabat-2005, Rabat, Health Ministry, epidemiology and disease control department (DELM) Scientific Association of the National Institute of Oncology (ASINO), 2009.
[13]	SELLAMI A and coll. Southern Tunisian Cancer Registry. Cancer Incidence 1997-19998.
[14]	KISSILE O., KALENGAYI MM, PASQUIER B and coll. Anatomoclinical and epidemiological Profile of nerve tumors in congolese. Pratical Carcinology in Africa 2005; 6: 43-46.
[15]	EL MADHI, T. EL AZZOUZI M, EL KHAMLICHIL A. Descriptive epidémiological profile of central nervous system tumors: About 903 case (1983-1992). Maghreb Medicine N°59.
[16]	TAO S, WARRINGTON NM, RUBIN JB. Why does Jack and not Jill, break his crown? Sex disparity in brains tumors. Biology of sex differences, 3. (2012).
[17]	LONJON M, MONDO L, LONJON N and coll. Clinical Pathways of glioblastomas and neuroradiology. Neurosurgery 2010; 56: 449-454.
[18]	FRENEL JS, BOTTI M, LOUSSOUARN D and coll. Pronostic and Predictive factors of response in adult cerebral gliomas Bull Cancer 2009; 96 (4): 357-367.
[19]	BIRNER P, TOUMANGELOVA-UZEIR K, NATCHEV S and coll. Expression of mutated isocitrate dehydrogenase-1 in glioma is associated with P53 and EGFR expression. Folia Neuropathology. 2011; 49(2):88-93.
[20]	2MELLAI M, PIAZZI A, CALDERA V and coll. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brains tumors. J Neuropathol. 2011; 105 (2): 345-357.
[21]	JEUKEN J, CORNELISSEN S, BOOTS-SPRENGER S and coll. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glials tumors. J Mol Diagn 2006; 8 (4): 4439.
[22]	MUKASA A, TAKAYANAGI S, SAITO K and coll. Significancy IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients, Cancer Sci. 2012; 103 (3): 587-592.

Cite This Article

Plain Text BibTeX RIS

APA Style

Kisile Mikuo Olive, Kabongo Mpolesha Jean Marie, Claudia Manini. (2021). Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. International Journal of Immunology, 9(2), 29-36. https://doi.org/10.11648/j.iji.20210902.12

Copy | Download

ACS Style

Kisile Mikuo Olive; Kabongo Mpolesha Jean Marie; Claudia Manini. Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. Int. J. Immunol. 2021, 9(2), 29-36. doi: 10.11648/j.iji.20210902.12

Copy | Download

AMA Style

Kisile Mikuo Olive, Kabongo Mpolesha Jean Marie, Claudia Manini. Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. Int J Immunol. 2021;9(2):29-36. doi: 10.11648/j.iji.20210902.12

Copy | Download

@article{10.11648/j.iji.20210902.12,
  author = {Kisile Mikuo Olive and Kabongo Mpolesha Jean Marie and Claudia Manini},
  title = {Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016},
  journal = {International Journal of Immunology},
  volume = {9},
  number = {2},
  pages = {29-36},
  doi = {10.11648/j.iji.20210902.12},
  url = {https://doi.org/10.11648/j.iji.20210902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20210902.12},
  abstract = {The goal is to determine immunohistochemical histopathological profile and biomolecular level of Central nerve Tumors in Kinshasa, DRC. According to the classification of the World Health Organization (WHO) 2016. Our study is described on a series of cases that were studied using standard histopathological techniques, before undergoing specific immunohistochemical techniques for the detection of anti-IDH1antibodies in gliomas and biomolecular ones in the search for 1p19q deletion. Central nerve tumors account for 0.18% of all conditions, over a period of time. Meningothelial-type meningioma was the most common (60.9%). The most affected age group is over 50. The distribution of tumors by sex shows a predominance of woman (67.1%). The gliomas had constituted 29.6% of all nerve tumors recorded over the period considered and whose predominance was constituted by oligoastrocytomas with 42.1%. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II oligoastrocytoma with 6.6%. Our study showed that central nerve tumors account for 0.18 of all conditions, gliomas are made up of 29.6% of all nerve tumors listed with a predominance of oligoastrocytomas. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016
AU - Kisile Mikuo Olive
AU - Kabongo Mpolesha Jean Marie
AU - Claudia Manini
Y1 - 2021/05/14
PY - 2021
N1 - https://doi.org/10.11648/j.iji.20210902.12
DO - 10.11648/j.iji.20210902.12
T2 - International Journal of Immunology
JF - International Journal of Immunology
JO - International Journal of Immunology
SP - 29
EP - 36
PB - Science Publishing Group
SN - 2329-1753
UR - https://doi.org/10.11648/j.iji.20210902.12
AB - The goal is to determine immunohistochemical histopathological profile and biomolecular level of Central nerve Tumors in Kinshasa, DRC. According to the classification of the World Health Organization (WHO) 2016. Our study is described on a series of cases that were studied using standard histopathological techniques, before undergoing specific immunohistochemical techniques for the detection of anti-IDH1antibodies in gliomas and biomolecular ones in the search for 1p19q deletion. Central nerve tumors account for 0.18% of all conditions, over a period of time. Meningothelial-type meningioma was the most common (60.9%). The most affected age group is over 50. The distribution of tumors by sex shows a predominance of woman (67.1%). The gliomas had constituted 29.6% of all nerve tumors recorded over the period considered and whose predominance was constituted by oligoastrocytomas with 42.1%. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II oligoastrocytoma with 6.6%. Our study showed that central nerve tumors account for 0.18 of all conditions, gliomas are made up of 29.6% of all nerve tumors listed with a predominance of oligoastrocytomas. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II.
VL - 9
IS - 2
ER -

Copy | Download

Author Information

Kisile Mikuo Olive

Pathological Anatomy Departmen, Medical School, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo
Kabongo Mpolesha Jean Marie

Pathological Anatomy Departmen, Medical School, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo
Claudia Manini

Pathological Anatomy Department, Hospital Center of San Giovanni Bosco, Turin, Italy

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Kisile Mikuo Olive, Kabongo Mpolesha Jean Marie, Claudia Manini. (2021). Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. International Journal of Immunology, 9(2), 29-36. https://doi.org/10.11648/j.iji.20210902.12

Copy | Download

ACS Style

Kisile Mikuo Olive; Kabongo Mpolesha Jean Marie; Claudia Manini. Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. Int. J. Immunol. 2021, 9(2), 29-36. doi: 10.11648/j.iji.20210902.12

Copy | Download

AMA Style

Kisile Mikuo Olive, Kabongo Mpolesha Jean Marie, Claudia Manini. Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016. Int J Immunol. 2021;9(2):29-36. doi: 10.11648/j.iji.20210902.12

Copy | Download

@article{10.11648/j.iji.20210902.12,
  author = {Kisile Mikuo Olive and Kabongo Mpolesha Jean Marie and Claudia Manini},
  title = {Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016},
  journal = {International Journal of Immunology},
  volume = {9},
  number = {2},
  pages = {29-36},
  doi = {10.11648/j.iji.20210902.12},
  url = {https://doi.org/10.11648/j.iji.20210902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20210902.12},
  abstract = {The goal is to determine immunohistochemical histopathological profile and biomolecular level of Central nerve Tumors in Kinshasa, DRC. According to the classification of the World Health Organization (WHO) 2016. Our study is described on a series of cases that were studied using standard histopathological techniques, before undergoing specific immunohistochemical techniques for the detection of anti-IDH1antibodies in gliomas and biomolecular ones in the search for 1p19q deletion. Central nerve tumors account for 0.18% of all conditions, over a period of time. Meningothelial-type meningioma was the most common (60.9%). The most affected age group is over 50. The distribution of tumors by sex shows a predominance of woman (67.1%). The gliomas had constituted 29.6% of all nerve tumors recorded over the period considered and whose predominance was constituted by oligoastrocytomas with 42.1%. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II oligoastrocytoma with 6.6%. Our study showed that central nerve tumors account for 0.18 of all conditions, gliomas are made up of 29.6% of all nerve tumors listed with a predominance of oligoastrocytomas. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II.},
 year = {2021}
}

Copy | Download